Innocare Pharma Limited Stock Performance
| INCPF Stock | USD 2.05 0.08 3.76% |
The company retains a Market Volatility (i.e., Beta) of 0.88, which attests to possible diversification benefits within a given portfolio. InnoCare Pharma returns are very sensitive to returns on the market. As the market goes up or down, InnoCare Pharma is expected to follow. At this point, InnoCare Pharma has a negative expected return of -0.64%. Please make sure to check out InnoCare Pharma's variance, skewness, as well as the relationship between the Skewness and day median price , to decide if InnoCare Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days InnoCare Pharma Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 2.3 B | |
| Total Cashflows From Investing Activities | -1.7 B |
InnoCare |
InnoCare Pharma Relative Risk vs. Return Landscape
If you would invest 326.00 in InnoCare Pharma Limited on September 27, 2025 and sell it today you would lose (121.00) from holding InnoCare Pharma Limited or give up 37.12% of portfolio value over 90 days. InnoCare Pharma Limited is currently producing negative expected returns and takes up 3.7758% volatility of returns over 90 trading days. Put another way, 33% of traded pink sheets are less volatile than InnoCare, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
InnoCare Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InnoCare Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as InnoCare Pharma Limited, and traders can use it to determine the average amount a InnoCare Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1684
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INCPF |
Based on monthly moving average InnoCare Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InnoCare Pharma by adding InnoCare Pharma to a well-diversified portfolio.
InnoCare Pharma Fundamentals Growth
InnoCare Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of InnoCare Pharma, and InnoCare Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InnoCare Pink Sheet performance.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0529 | |||
| Profit Margin | (1.96) % | |||
| Operating Margin | (1.61) % | |||
| Current Valuation | 2.26 B | |||
| Shares Outstanding | 1.76 B | |||
| Price To Book | 5.74 X | |||
| Price To Sales | 11.43 X | |||
| Revenue | 1.04 B | |||
| EBITDA | (13.84 M) | |||
| Cash And Equivalents | 6.25 B | |||
| Cash Per Share | 4.17 X | |||
| Total Debt | 1.2 B | |||
| Debt To Equity | 0.23 % | |||
| Book Value Per Share | 4.38 X | |||
| Cash Flow From Operations | 167.06 M | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 7.4 B | |||
About InnoCare Pharma Performance
By analyzing InnoCare Pharma's fundamental ratios, stakeholders can gain valuable insights into InnoCare Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if InnoCare Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if InnoCare Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. The company was incorporated in 2015 and is headquartered in Beijing, China. Innocare Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 531 people.Things to note about InnoCare Pharma performance evaluation
Checking the ongoing alerts about InnoCare Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for InnoCare Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InnoCare Pharma generated a negative expected return over the last 90 days | |
| InnoCare Pharma has high historical volatility and very poor performance | |
| InnoCare Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 1.04 B. Net Loss for the year was (64.55 M) with profit before overhead, payroll, taxes, and interest of 977.37 M. | |
| About 32.0% of the company shares are held by company insiders |
- Analyzing InnoCare Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InnoCare Pharma's stock is overvalued or undervalued compared to its peers.
- Examining InnoCare Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InnoCare Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of InnoCare Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InnoCare Pharma's pink sheet. These opinions can provide insight into InnoCare Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for InnoCare Pink Sheet analysis
When running InnoCare Pharma's price analysis, check to measure InnoCare Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InnoCare Pharma is operating at the current time. Most of InnoCare Pharma's value examination focuses on studying past and present price action to predict the probability of InnoCare Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InnoCare Pharma's price. Additionally, you may evaluate how the addition of InnoCare Pharma to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |